MACROGENICS, INC. Accrued Liabilities, Current
MACROGENICS, INC. (MGNX) had Accrued Liabilities, Current of $29.90 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $29.90M.
- 2026-03-31: Accrued Liabilities, Current $18.45M.
- 2025-12-31: Accrued Liabilities, Current $22.06M; Accrued Liabilities, Current as first filed $22.23M.
- 2025-09-30: Accrued Liabilities, Current $23.09M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $29.90M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $18.45M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $22.06M 10-Q · filed 2026-08-14 | $22.23M 10-K · filed 2026-03-09 |
| 2025-09-30 | $23.09M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $21.35M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $27.84M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $29.33M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $24.64M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $24.45M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $18.15M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $24.24M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $25.48M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $27.53M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $28.19M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $29.00M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $33.32M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $31.76M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $32.97M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $33.76M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $41.86M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $39.17M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $34.97M 10-Q · filed 2021-04-29 | |
| 2020-12-31 | $34.20M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $32.67M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $30.48M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $25.06M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $27.14M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $28.39M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $30.41M 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $28.85M 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $33.20M 10-K · filed 2020-02-25 | $33.02M 10-K · filed 2019-02-26 |
| 2018-09-30 | $38.48M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $37.18M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $30.49M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $38.58M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $25.50M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $22.32M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $17.96M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $16.13M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $15.37M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $12.34M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $9.69M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $11.71M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $9.12M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $8.30M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $7.00M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $7.93M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $4.03M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $3.31M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $2.74M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $3.58M 10-K · filed 2015-03-03 | $3.58M 10-K · filed 2014-03-20 |
| 2013-09-30 | $939.81K 10-Q · filed 2013-11-12 | |
| 2012-12-31 | $1.24M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |